What changed from existing technology?
This study used a special eye imaging technique to look at tiny blood vessels in the retina of children with growth hormone deficiency before and after treatment with growth hormone.
This is the first study to use OCTA to monitor retinal microvascular changes in children with GHD during GH therapy, providing a new method for assessing treatment effects on retinal vasculature.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 0
- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This method could potentially be used to monitor retinal vascular changes in children undergoing GH therapy, providing a non-invasive imaging tool for assessing treatment response.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.